A B S T R A C T The study of serum from a patient with C2 deficiency is described. The patient had an episode of pneumococcal meningitis at 5 mo of age with seizures and transient hemiparesis and apparent purpuric skin lesions. He was first admitted to the University of Minnesota Hospitals at 10 yr of age following the discovery of proteinuria accidentally by his mother. Since then he has been admitted repeatedly to this hospital with numerous clinical findings including arthralgia, recurrent abdominal pain, proteinuria, membranous nephropathy, malar butterfly rash, seizures, personality aberrations, and recurrent fever. In June 1971, the patient developed positive DNA and DNP antibodies and positive LE cells. When the C profile was studied before and after recognition of lupus, Clq, Cls, and C4 dropped. C3 levels were elevated as were C5, C6, and C7. C3 proactivator had been reduced in the patient even before he developed lupus. Also because of a traumatic renal biopsy leading to a perirenal hematoma, he required surgery and a blood transfusion. 1 h after blood transfusion, a C2 titer of 23 hemolytic units was detected. Almost immediately levels of C3, C5, C6, and C7 dropped. C8 and C9 remained elevated. The addition of C2 from normal blood permitted dramatic activation of C3.
INTRODUCTION
The association of complement deficiencies with recurrent infections and renal disease is gaining increasing importance. Clq (1-3), Clr (4-6), Cls (7), C2, and C3 deficient patients have been studied in our laboratories and also by other investigators (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . In most of these patients increased susceptibility to infections, vascular lesions, renal disease, and lupus-like syndromes have been observed. Pickering et al. (8) in these laboratories previously described a C2-deficient patient with chronic membranous glomerulonephritis. This patient has now developed clear evidence of lupus erythematosus (LE)1 and a comparative complement profile determined before and after recognition of lupus is reported in this study.
Briefly, this patient had an episode of pneumococcal meningitis at 5 mo of age with seizures and transient hemiparesis and apparent purpuric skin lesions. At 5 yr he had frequent sore throats and since then has had numerous episodes of high fever without localizing symptoms. Other illnesses have included infectious mononucleosis at 7 yr of age, atypical pneumonia at age 8, and meningococcemia at 9 yr of age. In addition, he has suffered throughout childhood with unexplained episodes of abdominal pains.
He was first admitted to the University of Minnesota Hospital in November 1967 at 10 yr of age following the discovery that he had proteinuria. The mother had tested the patient's urine with Albustix since these were available to her because a younger sibling had had steroid-responsive idiopathic nephrotic syndrome. At this time he had spiking fevers, elevated sedimentation rate, proteinuria, hematuria, and hypertension. The second admission was in May 1968 with a marked increase in severity of his disease. Prednisone and azathioprine were begun at this time and his urine became protein free. The third admission was in December 1969 because of increase in temperature and complaints of diffuse abdominal pains. A facial rash was noted at this time which became worse in sunlight. A kidney biopsy was repeated and showed chronic glomerulonephritis predominantly of membranous type. An extensive work-up for lupus erythematosus was negative. In 1970, he was admitted to the hospital on two occasions for abdominal pain, proteinuria, malar rash in butterfly distribution, seizures, personality aberrations, and recurrent fever. Following an appendectomy in January 1971, he had severe postoperative infection with high fevers which did not respond well to antibiotics. were prepared according to the methods described previously (5, 20) .
Assays of total complement CH5O and of the C components. Total CH50 was carried out as previously described (21) . Functionally pure C components for the assay of these components and EAClgp-7 HU for use in assay of C8 and C9 were obtained from Cordis Laboratories (Miami, Fla.) and the assays were carried out according to the method described by Nelson et al. (19) . The experimental error of the C components 1-9 ranged between 5 and 10%. Immunochemical assays of these components Clq, Cls, and C3PA were carried out by the Mancini technique2 (22) .
Immunofluorescent and light microscopy studies. Tissue was obtained by kidney biopsy over a period of 5 yr, and was studied by immunofluorescent and light microscopy as described previously (4) . Monospecific antisera against human IgG, IgM, IgA, Blc globulin, Clq, and properdin were tagged with fluorescein isothiocyanate (FITC) as described earlier (23, 24) . Table I presents observations on the total hemolytic complement and complement components observed in the patient's serum before and after recognizable lupus.
RESULTS
As will be seen from the table, prior to development of clear clinical manifestations of lupus, the patient had a complement profile which showed unmeasurable C2 and moderate reduction of Cl and C4 accompanied by elevations of C3, C5, and C9. C6, C7, and C8 were in the normal range. This profile was accompanied by progressive renal disease classified as membranous glomerulonephritis. After he developed clear clinical evidence of lupus with the appearance of anti-DNA and DNP antibodies in the blood and a positive LE clot test, his complement profile changed in degree. Thus, it will be seen on the table that Cl and C4 dropped to very low levels, while C3 remained elevated and the remaining components did not show any significant change with the alteration of the clinical state.
Following a renal biopsy, the patient developed a perirenal hematoma and required transfusion with 1 U of whole blood. Blood samples for complement assays were drawn serially and a complement profile of each sample was determined. Table III are immunochemical determinations of Clq, Cls, C4, C3, C5, C6, C8, C9, the C3 proactivator, and properdin of the patient's serum as observed before and after recognizable clinical lupus, following transfusion of blood and subsequent steroid treatment. It will be seen in the table that the Clq levels, which were lower than normal before development of lupus, dropped to extremely low levels with change in clinical state. Following the transfusion of whole blood, the concentration of Clq was increased where it has remained with minor fluctuations. The levels of Cls which had been lower than normal in the pre-lupus phase, were also reduced after he developed recognizable clinical lupus. These levels were not appreciably altered by transfusion. Levels of C4 were also low prior to development of clinical lupus. The concentration of this component dropped a little with the change in clinical state. The concentration of this component was increased after transfusion, but promptly returned to the pretransfusion low levels within 6 h after the transfusion. Immunochemical determination also revealed a paradoxical elevation of C3 like that which had been observed upon hemolytic analyses. Following transfusion a decline of concentrations of this component was observed followed by a return to the elevated concentration by 48 h after transfusion. The elevated levels of C5 and C6 observed before the appearance of clinical lupus persisted with the change in clinical state and no dramatic alterations in immunochemically determined concentrations of these components were noted after transfusion. C3 proactivator and properdin did not change dramatically.
The results of the immunofluorescent staining of the kidney biopsy and the period of time when therapy was administered to the patient are summarized in Table IV . As indicated in the table, from 1967 to 1970, the kidney biopsy tissues were stained with FITC-tagged antisera against Bic, IgG, fibrin, IgA, and Clq. The intensity of immunofluorescence is arbitrarily graded as 0, 1 +, 2 +, and 3 +. There was a clear demonstration of positive glomerular staining for IgG (2-3 +), IgM (3 +) on one occasion, much weaker staining for C3 (0-2 +), and on one biopsy Clq (3 +) was demonstrable. Light micros- It is provocative that the C3 proactivator had been reduced even before a laboratorv diagnosis of lupus could be made. This could account for the recurrent infections in this patient. Root et al. (25) have demonstrated that their guinea pigs deficient in C4 appear to be in good health under laboratory conditions. This may be a reflection of the role of the alternate pathway in host resistance to bacterial infections. In our patient, after recognizable lupus, the kidney biopsy showed an intensive staining of C3 by immunofluorescence which had previously been only weakly positive. Properdin and IgA were also present in the glomerular capillary loops. These findings suggest that the alternate pathway is indeed being engaged even though C3, C5, and C6 levels remain high.
These observations suggest that in lupus both the classical pathway of complement activation, and the alternate pathway can be activated by the patient's serum. Evidence from studies of Agnello, de Bracco, and Kunkel (13) are consonant with this finding. In the absence of C2, the so-called alternate pathway might be expected to be active. If C2 were present' utilization of the primary pathway would then be anticipated.
This view is consonant with our observations of changes in the C profile after blood transfusion in this patient. 1 h after a blood transfusion, a C2 titer of 23 hemolytic units was detected. Although this is still a low level, this was the first time C2 had ever been detectable in the patient's serum. Almost immediately, levels of C3, C5, C6, and C7 dropped. C8 and C9 remained elevated. The latter finding is of interest in light of Ruddy's report that C9 levels are elevated in lupus (26 The family history also is of concern. The maternal grandmother had had unexplained skin ulcers and a brother developed nephrosis. Although possibly fortuitous these associations should prompt a detailed family study C2 Deficiency: Development of Lupus Erythematosusof complement profiles. These studies will be carried out. It is also probable that the absence of C2 has been important in preventing more severe complement-mediated glomerular injury. Although histologic evidence of membranous nephropathy was present, proteinuria was always mild and C3 was detected on the glomeruli only in trace amounts.
A single association of C2 deficiency, increased infections, and lupus complicating existing renal disease, although challenging, could be fortuitous. One example of this association, however, does not stand alone. Lachman has observed a patient with purpura in one patient having a deficiency of C2, Leddy has observed a C2-deficient patient with a syndrome like dermatomyositis to occur, Osterland has observed a C2 deficient patient with lupus erythematosus to occur (personal communication), and Agnello et al. have reported a C2 deficient patient who developed lupus (13) . In contradistinction to our observation, the case by Agnello et al. showed no evidence of activation of the earlier complement components. Studies of the C3PA in their case would be of interest. It thus seems clear that the rare deficiency in production of C2 predisposes to serious susceptibility to infection, vascular and mesenchymal disease as well as to renal disease and a lupus syndrome. Similar susceptibilities to infection, renal disease, and a lupus-like syndrome associated with other deficiencies of early complement components indicates that this part of the complement system represents a most significant defense against the development of such disorders. Much investigation in the future is needed to clarify these provocative relationships.
